scholarly journals FAS and FASL variations in outcomes of tobacco- and alcohol-related head and neck squamous cell carcinoma patients

Tumor Biology ◽  
2020 ◽  
Vol 42 (7) ◽  
pp. 101042832093849
Author(s):  
Ericka Francislaine Dias Costa ◽  
Tathiane Regine Penna Lima ◽  
Leisa Lopes-Aguiar ◽  
Guilherme Augusto Silva Nogueira ◽  
Marília Berlofa Visacri ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Multiple Logistic Regression Analysis ◽  
Neck Squamous Cell Carcinoma ◽  
Response To Treatment ◽  
Single Nucleotide Variants ◽  
Single Nucleotide ◽  
Apoptosis Pathway

Radiotherapy and cisplatin lead to cell killing in head and neck squamous cell carcinoma patients, but adverse events and response to treatment are not the same in patients with similar clinicopathological aspects. The aim of this prospective study was to evaluate the roles of TP53 c.215G > C, FAS c.-671A > G, FAS c.-1378G > A, FASL c.-844 C > T, CASP3 c.-1191A > G, and CASP3 c.-182-247G > T single nucleotide variants in toxicity, response rate, and survival of cisplatin chemoradiation-treated head and neck squamous cell carcinoma patients. Genomic DNA was analyzed by polymerase chain reaction for genotyping. Differences between groups of patients were analyzed by chi-square test or Fisher’s exact test, multiple logistic regression analysis, and Cox hazards model. One hundred nine patients with head and neck squamous cell carcinoma were enrolled in study. All patients were smokers and/or alcoholics. Patients with FAS c.-671GG genotype, FAS c.-671AG or GG genotype, and FASL c.-844CC genotype had 5.52 (95% confidence interval (CI): 1.42–21.43), 4.03 (95% CI: 1.51–10.79), and 5.77 (95% CI: 1.23–27.04) more chances of presenting chemoradiation-related anemia of grades 2–4, lymphopenia of grade 3 or 4, and ototoxicity of all grades, respectively, than those with the remaining genotypes. FAS c.-671GG genotype was also seen as an independent predictor of shorter event-free survival (hazard ratio (HR): 2.05; P  = 0.007) and overall survival (HR: 1.83; P  = 0.02) in our head and neck squamous cell carcinoma patients. These findings present, for the first time, preliminary evidence that inherited abnormalities in apoptosis pathway, related to FAS c.-671A > G and FASL c.-844 C > T single nucleotide variants, can alter toxicity and survival of tobacco- and alcohol-related head and neck squamous cell carcinoma patients homogeneously treated with cisplatin chemoradiation.

scholarly journals Single Nucleotide Polymorphism of MSH3 Gene Alters Head and Neck Squamous-Cell Carcinoma Risk in North-India

2017 ◽  
Vol 14 (1) ◽  
pp. 27-31 ◽  
Author(s):  
Suresh Kumar Yadav ◽  
Shalini Gupta ◽  
Madan Lal Brahma Bhatt ◽  
Durga Prasad Mishra ◽  
Dayalanand Roy ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Single Nucleotide Polymorphism ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
North India ◽  
Nucleotide Polymorphism ◽  
Single Nucleotide ◽  
Carcinoma Risk

scholarly journals Impact of gene polymorphisms on toxicity and response rate in head and neck squamous cell carcinoma: a literature review

2022 ◽  
Author(s):  
hamid abbaszadeh ◽  
Mahdieh Rajabi-Moghaddam
Keyword(s):  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Gene Polymorphisms ◽  
Response To Therapy ◽  
Neck Squamous Cell Carcinoma ◽  
Response To Treatment ◽  
The Impact

Abstract Advanced head and neck squamous cell carcinoma (HNSCC) is treated with radiotherapy, chemotherapy, targeted therapy or a combination of these treatments. Variations in toxicity and response to therapy are observed among patients despite similar clinicopathologic characteristics which are attributed to single nucleotide polymorphisms (SNPs). The aim of this review was to evaluate the impact of SNPs on toxicity and response to therapy in HNSCCs. A web-based search of all original articles about the impact of gene polymorphisms on toxicity and response to therapy in HNSCCs was done until September 2021 using international English language databases including Google Scholar, Scopus, PubMed and Web of science. Findings were categorized by type of treatment (radiotherapy, chemotherapy, targeted therapy, or combination therapy). In each category, studies related to growth control genes, cell proliferation, apoptosis, DNA repair genes, antioxidant and drug detoxification genes, genes of drug metabolizing enzymes, tissue remodeling genes and genes of antibody-dependent cellular cytotoxicity were discussed separately. Among studied SNPs with probable impact on toxicity and response to therapy are XRCC1, XRCC3, RAD51, Ku70, NBN, CAT, GSTP1, GSTT1, GSTM1, XPD, XPC, ERCC1, MMP3, ACSL6, EXO1, CXP2D6, FcγRIIIa, AurkA, and EGFR. Understanding gene polymorphisms will help us move toward personalized medicine and determine which patients will actually benefit from therapies for HNSCCs. By examining the SNPs, it is possible to make predictions about the patient's response to treatment or development of toxicity after treatment, and if necessary, make changes in the patient's treatment regimen.

scholarly journals The Aurora-Kinase A Phe31-Ile polymorphism as possible predictor of response to treatment in head and neck squamous cell carcinoma

Oncotarget ◽  
2018 ◽  
Vol 9 (16) ◽  
pp. 12769-12780 ◽  
Author(s):  
Alexander Baumann ◽  
Anna Maria S. Buchberger ◽  
Guido Piontek ◽  
Dominik Schüttler ◽  
Martina Rudelius ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Aurora Kinase ◽  
Neck Squamous Cell Carcinoma ◽  
Response To Treatment ◽  
Aurora Kinase A ◽  
Kinase A

scholarly journals Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study

2019 ◽  
Vol 65 (10) ◽  
pp. 1267-1275 ◽  
Author(s):  
Renaud Garrel ◽  
Martine Mazel ◽  
Françoise Perriard ◽  
Marie Vinches ◽  
Laure Cayrefourcq ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Response To Treatment ◽  
Rank Test ◽  
Response To Chemotherapy

Abstract BACKGROUND This prospective multicenter study evaluated the prognostic value of circulating tumor cells (CTCs) in relapsing nonoperable or metastatic head and neck squamous cell carcinoma (rHNSCC) treated by chemotherapy and cetuximab. METHODS In 65 patients suitable for analyses, peripheral blood was taken at day 0 (D0) D7, and D21 of treatment for CTC detection by CellSearch®, EPISPOT, and flow cytometry (FCM). Progression-free survival (PFS) was assessed with the Kaplan–Meier method and compared with the log-rank test (P < 0.05). RESULTS At D0, CTCs were detected with EPISPOT, CellSearch, and FCM in 69% (45/65), 21% (12/58), and 11% (7/61) of patients, respectively. In the patients tested with all 3 methods, EPISPOT identified 92% (36/39), 92% (35/38), and 90% (25/28) of all positive samples at D0, D7, and D21, respectively. Median PFS time was significantly lower in (a) patients with increasing or stable CTC counts (36/54) from D0 to D7 with EPISPOTEGFR (3.9 vs 6.2 months; 95% CI, 5.0–6.9; P = 0.0103) and (b) patients with ≥1 CTC detected with EPISPOT or CellSearch® (37/51) (P = 0.0311), EPISPOT or FCM (38/54) (P = 0.0480), and CellSearch or FCM (11/51) (P = 0.0005) at D7. CONCLUSIONS CTCs can be detected before and during chemotherapy in patients with rHNSCC. D0–D7 CTC kinetics evaluated with EPISPOTEGFR are associated with the response to treatment. This study indicates that CTCs can be used as a real-time liquid biopsy to monitor the early response to chemotherapy in rHNSCC. ClinicalTrials.gov Identifier NCT02119559

Sign in / Sign up

Export Citation Format

Share Document